BIOMAT Database Logo BIOMAT Database Logo

Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). 2003

F Millot, and H Esperou, and P Bordigoni, and J-H Dalle, and M Michallet, and G Michel, and J L Bourhis, and M Kuenz, and D Blaise, and F Garban, and E Plouvier, and A Rome, and J Guilhot, and F Guilhot
Service d'oncologie hématologique et de thérapie cellulaire, Centre Hospitalier Universitaire, Hôpital Jean Bernard, Poitiers 86000, France. f.millot@chu-poitiers.fr

To determine the results of allogeneic hematopoietic stem cell (HSC) transplantation for chronic myelogenous leukemia (CML) at various stages of the disease in children, a retrospective analysis was carried out on the outcome of transplants performed on 76 children and teenagers with CML between 1982 and 1998. In all, 60 patients were transplanted from a matched sibling donor (MSD) and 16 from a matched unrelated donor (MUD). There was a higher incidence of acute graft-versus-host disease after MUD transplantation (P<10(-3)). The main cause of death was transplant-related toxicity in both groups. In MSD recipients, the probability of relapse at 5 years for patients transplanted in the first chronic phase was lower than in patients transplanted in the advanced phase (relative risk (rr)=5.90; 95% confidence interval (CI), 1.85-18.82, P<0.01). The estimated 5-year event-free survival (EFS) rate was higher after MSD vs MUD transplantation (61% (95% CI, 48-73%) vs 27% (95% CI, 4-49%), rr=0.25, P<10(-3)). In children transplanted from MSD, the 5-year EFS was higher when transplantation was performed in the first chronic phase vs the advanced phases (73% (95% CI, 59-87%) vs 32% (95% CI, 10-54%), P<10(-3)). Disease status at transplantation was the unique factor influencing survival in patients undergoing transplantation from MSD with a better outcome for those transplanted in the first chronic phase. Allogeneic HSC offers a possibility of curing childhood CML with a significant advantage for patients transplanted in chronic phase using a human leukocyte antigen-identical sibling donor.

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D014019 Tissue Donors Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients. Organ Donors,Donors,Ovum Donors,Semen Donors,Transplant Donors,Donor,Donor, Organ,Donor, Ovum,Donor, Semen,Donor, Tissue,Donor, Transplant,Donors, Organ,Donors, Ovum,Donors, Semen,Donors, Tissue,Donors, Transplant,Organ Donor,Ovum Donor,Semen Donor,Tissue Donor,Transplant Donor

Related Publications

F Millot, and H Esperou, and P Bordigoni, and J-H Dalle, and M Michallet, and G Michel, and J L Bourhis, and M Kuenz, and D Blaise, and F Garban, and E Plouvier, and A Rome, and J Guilhot, and F Guilhot
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
February 2011, British journal of haematology,
F Millot, and H Esperou, and P Bordigoni, and J-H Dalle, and M Michallet, and G Michel, and J L Bourhis, and M Kuenz, and D Blaise, and F Garban, and E Plouvier, and A Rome, and J Guilhot, and F Guilhot
Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
August 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
F Millot, and H Esperou, and P Bordigoni, and J-H Dalle, and M Michallet, and G Michel, and J L Bourhis, and M Kuenz, and D Blaise, and F Garban, and E Plouvier, and A Rome, and J Guilhot, and F Guilhot
Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
February 2015, Bone marrow transplantation,
F Millot, and H Esperou, and P Bordigoni, and J-H Dalle, and M Michallet, and G Michel, and J L Bourhis, and M Kuenz, and D Blaise, and F Garban, and E Plouvier, and A Rome, and J Guilhot, and F Guilhot
Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
May 2020, Journal of hematology & oncology,
F Millot, and H Esperou, and P Bordigoni, and J-H Dalle, and M Michallet, and G Michel, and J L Bourhis, and M Kuenz, and D Blaise, and F Garban, and E Plouvier, and A Rome, and J Guilhot, and F Guilhot
Reduced-intensity conditioning followed by allogeneic transplantation in pediatric malignancies: a report from the Société Française des Cancers de l'Enfant and the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
November 2013, Bone marrow transplantation,
F Millot, and H Esperou, and P Bordigoni, and J-H Dalle, and M Michallet, and G Michel, and J L Bourhis, and M Kuenz, and D Blaise, and F Garban, and E Plouvier, and A Rome, and J Guilhot, and F Guilhot
Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
March 2016, Bone marrow transplantation,
F Millot, and H Esperou, and P Bordigoni, and J-H Dalle, and M Michallet, and G Michel, and J L Bourhis, and M Kuenz, and D Blaise, and F Garban, and E Plouvier, and A Rome, and J Guilhot, and F Guilhot
Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).
May 2017, Bone marrow transplantation,
F Millot, and H Esperou, and P Bordigoni, and J-H Dalle, and M Michallet, and G Michel, and J L Bourhis, and M Kuenz, and D Blaise, and F Garban, and E Plouvier, and A Rome, and J Guilhot, and F Guilhot
Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
October 2011, Haematologica,
F Millot, and H Esperou, and P Bordigoni, and J-H Dalle, and M Michallet, and G Michel, and J L Bourhis, and M Kuenz, and D Blaise, and F Garban, and E Plouvier, and A Rome, and J Guilhot, and F Guilhot
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).
January 2005, Bone marrow transplantation,
F Millot, and H Esperou, and P Bordigoni, and J-H Dalle, and M Michallet, and G Michel, and J L Bourhis, and M Kuenz, and D Blaise, and F Garban, and E Plouvier, and A Rome, and J Guilhot, and F Guilhot
Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
March 2014, Bone marrow transplantation,
Copied contents to your clipboard!